Status:
UNKNOWN
Goal Oriented Strategy to Preserve Ejection Fraction Trial
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in ...
Detailed Description
Rationale: The current strategy in patients with pulmonary arterial hypertension (PAH)is to improve exercise capacity which can be achieved by decreasing pulmonary vascular resistance (PVR) and subse...
Eligibility Criteria
Inclusion
- Idiopathic or heritable pulmonary arterial hypertension
- New York Heart Association (NYHA) functional class II or III
Exclusion
- Other causes of pulmonary arterial hypertension (i.e. collagen vascular disease, congenital heart disease, chrono-thromboembolic pulmonary hypertension, pulmonary venous hypertension, left heart failure, hypoxemic lung disease)
- Pulmonary arterial hypertension targeted therapies before study inclusion
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03236818
Start Date
May 1 2013
End Date
September 1 2017
Last Update
August 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center, dept Pulmonary diseases
Amsterdam, Netherlands, 1081 HV